Revance Announces BELMONT Phase 2 Clinical Data to Be Presented at the 2017 American Academy of Dermatology (AAD) Annual Meet...
March 03 2017 - 8:00AM
Business Wire
- Additional Presentation Affirms Use of
Patient Questionnaires in Assessing Frown Lines -
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology
company developing botulinum toxin products for use in aesthetic
and therapeutic indications, today announced presentation of
clinical data from the company’s BELMONT Phase 2 study of
DaxibotulinumtoxinA Injectable (RT002) at the 2017 American Academy
of Dermatology (AAD) Annual Meeting, taking place at the Orange
County Convention Center in Orlando, Florida, March 3-7, 2017.
BELMONT was the company’s Phase 2 active comparator,
placebo-controlled, multi-center study to evaluate the safety,
efficacy, and duration of effect of RT002 injectable for the
treatment of glabellar (frown) lines, the 24-week results of which
were reported in October 2015. Findings from a patient’s
perspective study also being reported at the AAD annual meeting
confirm the content validity of patient questionnaires in measuring
the impact of frown lines.
Scheduled data presentations at 2017 AAD Annual Meeting:
Poster Presentation: “Duration and Onset of Glabellar
Frown Line Reduction after an Injection of DaxibotulinumtoxinA:
Results of the BELMONT Study”, March 3, 1:30 PM to 1:35 PM ET,
Orlando, Florida
A poster highlights final data from the BELMONT Phase 2 active
comparator and placebo-controlled study of RT002 injectable for the
treatment of moderate to severe glabellar lines in adults.
Poster Presentation: “Impacts of Glabellar Facial Lines
– A Patient Perspective”, March 3, 2:15 PM to 2:20 PM ET, Orlando,
Florida
A second poster reports on findings validating the Patient Frown
Wrinkle Severity (PFWS) assessment, currently being used in
Revance’s SAKURA Phase 3 clinical program, and two recently
developed questionnaires, the Frown Line Impact Scale (FLIS) and
the Facial Age Self Evaluation (FASE) scale.
“Physician interest continues to mount for our BELMONT results,
and AAD provides an important opportunity to showcase our
differentiated clinical findings, including increased response
rates and extended duration of effect of RT002 compared to the
market-leading neurotoxin,” said Dan Browne, President and Chief
Executive Officer at Revance. “A content validity study also
examines our innovation of clinical assessment tools, further
underscoring our commitment to delineate the patient experience and
outcomes.”
About Revance Therapeutics, Inc.
Revance, a Silicon Valley-based biotechnology company, is
committed to the advancement of remarkable science. The company is
developing a portfolio of products for aesthetic medicine and
underserved therapeutic specialties, including dermatology,
orthopedics and neurology. Revance’s science is based upon a
proprietary peptide technology, which when combined with active
drug molecules, may help address current unmet needs. Revance’s
initial focus is on developing daxibotulinumtoxinA, the company’s
highly purified botulinum toxin, for a broad spectrum of aesthetic
and therapeutic indications, including facial wrinkles and muscle
movement disorders.
The company’s lead drug candidate, DaxibotulinumtoxinA for
Injection (RT002), is currently in development for the treatment of
glabellar lines, cervical dystonia and plantar fasciitis with the
potential to be the first long-acting neuromodulator. The company
holds worldwide rights for all indications of RT002 injectable and
RT001 topical and the pharmaceutical uses of its proprietary
peptide technology platform. More information on Revance may be
found at www.revance.com.
“Revance Therapeutics” and the Revance logo are registered
trademarks of Revance Therapeutics, Inc.
Forward-Looking Statements
This press release contains forward-looking statements,
including statements related to the process and timing of, and
ability to complete, current and anticipated future clinical
development of our investigational drug product candidates,
including but not limited to initiation and design of clinical
studies for current and future indications, related results and
reporting of such results; statements about our business strategy,
timeline and other goals and market for our anticipated products,
plans and prospects; and statements about our ability to obtain
regulatory approval; and potential benefits of our drug product
candidates and our technologies.
Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially
from our expectations. These risks and uncertainties include, but
are not limited to: the outcome, cost, and timing of our product
development activities and clinical trials; the uncertain clinical
development process, including the risks that interim results are
not indicative of final results and that clinical trials may not
have an effective design or generate positive results; our ability
to obtain and maintain regulatory approval of our drug product
candidates; our ability to obtain funding for our operations; our
plans to research, develop, and commercialize our drug product
candidates; our ability to achieve market acceptance of our drug
product candidates; unanticipated costs or delays in research,
development, and commercialization efforts; the applicability of
clinical study results to actual outcomes; the size and growth
potential of the markets for our drug product candidates; our
ability to successfully commercialize our drug product candidates
and the timing of commercialization activities; the rate and degree
of market acceptance of our drug product candidates; our ability to
develop sales and marketing capabilities; the accuracy of our
estimates regarding expenses, future revenues, capital requirements
and needs for financing; our ability to continue obtaining and
maintaining intellectual property protection for our drug product
candidates; and other risks. Detailed information regarding factors
that may cause actual results to differ materially from the results
expressed or implied by statements in this press release may be
found in Revance's periodic filings with the Securities and
Exchange Commission (the "SEC"), including factors described in the
section entitled "Risk Factors" of our annual report on Form 10-K
filed February 28, 2017. These forward-looking statements speak
only as of the date hereof. Revance disclaims any obligation to
update these forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170303005166/en/
Investors:Revance Therapeutics, Inc.Jeanie Herbert,
714-325-3584jherbert@revance.comorBurns McClellanAmi Bavishi,
212-213-0006abavishi@burnsmc.comorTrade Media:Nadine Tosk,
504-453-8344nadinepr@gmail.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Apr 2023 to Apr 2024